EGFR-IN-26
EGFR-IN-26 is a EGFR inhibitor extracted from patent WO2019162323A1 compound I-028. EGFR-IN-26 can be used for the research of cancer[1].
Product Specifications
CAS Number
2375470-64-5
UNSPSC
12352005
Target
VEGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/egfr-in-26.html
Solubility
10 mM in DMSO
Smiles
O=C(C1=CC(C2=C(OC)C=CN=C2)=NC=C1)NC3=NC4=C(N3CC(C)(C)O)C=CC(C5CCN(CC5)C)=C4
Molecular Formula
C29H34N6O3
Molecular Weight
514.62
References & Citations
[1]BOESE D, et, al. New benzimidazole compounds and derivatives as egfr inhibitors. WO2019162323A1.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC471730-100 1x 100 µL
MMP3 (Marker of Metastasis and Rheumatoid Arthritis) (MMP3/1730), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC471082-100 1x 100 µL
MHC II (HLA-DRA) (19-26.1), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 